Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a good week for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shareholders, because the company has just released its latest quarterly results, and the shares gained 5.0% to US$8.21. Revenues US$725m disappointed slightly, at2.7% below what the analysts had predicted. Profits were a relative bright spot, with statutory per-share earnings of US$0.07 coming in 17% above what was anticipated. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

After the latest results, the four analysts covering Amneal Pharmaceuticals are now predicting revenues of US$3.00b in 2025. If met, this would reflect a modest 5.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to soar 1,664% to US$0.19. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.01b and earnings per share (EPS) of US$0.14 in 2025. Although the revenue estimates have not really changed, we can see there's been a very substantial lift in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.

Check out our latest analysis for Amneal Pharmaceuticals

The consensus price target was unchanged at US$12.00, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Amneal Pharmaceuticals, with the most bullish analyst valuing it at US$13.00 and the most bearish at US$11.00 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Amneal Pharmaceuticals' growth to accelerate, with the forecast 11% annualised growth to the end of 2025 ranking favourably alongside historical growth of 8.8% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 7.9% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Amneal Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Amneal Pharmaceuticals following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$12.00, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Amneal Pharmaceuticals analysts - going out to 2027, and you can see them free on our platform here.

Even so, be aware that Amneal Pharmaceuticals is showing 3 warning signs in our investment analysis , and 2 of those are concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.